Results of 2020 Annual General Meeting

RNS Number : 7165O

e-Therapeutics plc

02 June 2020

 

e-therapeutics plc

('e-therapeutics' or the 'Company')

Results of 2020 Annual General Meeting

Oxford, UK, 2 June 2020 - e-therapeutics plc (AIM: ETX) is pleased to announce that all resolutions as set out in the Notice of Annual General Meeting dated 25 March 2020 were duly passed by shareholders of the Company at the Annual General Meeting held earlier today.

-Ends-

For more information, please contact:

e-therapeutics plc Ali Motazavi, Executive Chairman	Tel: [phone] www.etherapeutics.co.uk
Numis Securities Limited Freddie Barnfield/Duncan Monteith (Nominated Adviser) James Black (Corporate Broking)	Tel: [phone] www.numis.com
FTI Consulting Simon Conway/Stephanie Cuthbert	Tel: [phone] Email:  [e-mail]

  About e-therapeutics

e-therapeutics is an Oxford, UK-based company with a unique and powerful computer-based approach to drug discovery, founded on our industry-leading expertise in network biology.

We have created two proprietary, unique and productive technologies. The first is Network-driven Drug Discovery ("NDD"), which is based on cutting-edge network science, statistics, machine learning and artificial intelligence. NDD allows the more efficient discovery of new and better drugs and has been validated in multiple and diverse areas of biology.

The second is Genome Associated Interaction Networks ("GAINs"). GAINs is a revolutionary and entirely novel approach to functional genomics, based on the same validated network biology and analytics expertise that underpins our NDD technologies. GAINs analyses human genetic data to provide a deep and valuable understanding of the mechanisms that cause disease. GAINs has the potential to uncover unrecognised disease processes and pathways and can enable the discovery of novel drugs, diagnostics and biomarkers in a way not previously possible from population genomics data, such as genome-wide association studies ("GWAS").

We have deployed our highly productive drug discovery platform technologies to develop our own IP-protected, pre-clinical drug discovery programmes that are available to partners seeking to acquire or in-license novel and differentiated assets.

We have partnerships with Novo Nordisk in Type-2 diabetes and a US-based, top 5 pharmaceutical company in neurodegeneration. We are working on different types of collaborative partnerships with biotech, pharma and other technology companies to create sustainable mutual value.  

 

END

 

 

RAGBXGDLIDGDGGD